These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 25715325)

  • 21. Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Bar J; Onn A
    Clin Lung Cancer; 2012 Jul; 13(4):267-79. PubMed ID: 22154113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
    Silvestri GA; Rivera MP
    Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapies in solid tumours: results and promises.
    Pantaleo MA; Saponara M; Nannini M; Biasco G
    Minerva Med; 2007 Oct; 98(5):603-23. PubMed ID: 18043567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
    Nakata A; Gotoh N
    Expert Opin Ther Targets; 2012 Aug; 16(8):771-81. PubMed ID: 22762482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized medicine for metastatic breast cancer.
    Chen TW; Bedard PL
    Curr Opin Oncol; 2013 Nov; 25(6):615-24. PubMed ID: 24097103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant kinase signaling: lessons from head and neck cancer.
    Nelson EG; Grandis JR
    Future Oncol; 2007 Jun; 3(3):353-61. PubMed ID: 17547530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Saba NF; Khuri FR; Shin DM
    Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
    Ray M; Salgia R; Vokes EE
    Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Liao BC; Lin CC; Yang JC
    Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents.
    Gridelli C; Rossi A; Maione P
    Oncogene; 2003 Sep; 22(42):6629-38. PubMed ID: 14528288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New molecular targeted therapies integrated with radiation therapy in lung cancer.
    Provencio M; Sánchez A; Garrido P; Valcárcel F
    Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
    Gilbert J; Argiris A
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successes and limitations of targeted cancer therapy in breast cancer.
    Curigliano G; Criscitiello C
    Prog Tumor Res; 2014; 41():15-35. PubMed ID: 24727984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Triage Trials in Colorectal Cancer.
    O'Hara MH; Hamilton SR; O'Dwyer PJ
    Cancer J; 2016; 22(3):218-22. PubMed ID: 27341602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapy in head and neck cancer.
    Bianchini C; Ciorba A; Pelucchi S; Piva R; Pastore A
    Tumori; 2011; 97(2):137-41. PubMed ID: 21617705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer.
    Tobin NP; Foukakis T; De Petris L; Bergh J
    J Intern Med; 2015 Dec; 278(6):545-70. PubMed ID: 26373821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Cancer Therapy: The Next Generation of Cancer Treatment.
    Baudino TA
    Curr Drug Discov Technol; 2015; 12(1):3-20. PubMed ID: 26033233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.